Now Reading: Mankind Pharma Q2 profit surges up to 39% to ₹712 crore
-
01
Mankind Pharma Q2 profit surges up to 39% to ₹712 crore
The Story in Brief
Mankind Pharma reported a 37.7% to 39.2% year-on-year rise in consolidated net profit for the September quarter, with CNBCTV18 putting the figure at ₹712 crore while The Hans India and Business Standard report ₹716 crore. Revenue from operations grew 17.3% to ₹4,338 crore, driven by strong domestic business growth of 15.9% and a 33% jump in international revenue, supported by the specialty portfolio of Bharat Serums and Vaccines.
Vice Chairman Rajeev Juneja said the firm’s recent acquisition of Armed Cell Therapeutics marks its entry into next-generation CAR-T therapies. The consumer healthcare business posted muted 1.2% growth amid slower category offtake. The board also approved schemes to merge wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent, with an appointed date of April 1, 2027, subject to NCLT and regulatory approvals. Shares rose over 3% on the BSE on October 26.
Indian Opinion Analysis
All four sources report Mankind Pharma’s Q2 profit jump of roughly 37 to 39% and revenue rise of 17%, with factual figures that align closely. CNBCTV18 leads with the exact profit figure of ₹712 crore and the 39% rise, while The Hans India and Business Standard report ₹716 crore and 37.7%, a minor difference in rounding. CNBCTV18 emphasises the merger plans for its subsidiaries and the board’s approval, whereas The Hans India and Business Standard quote Vice Chairman Rajeev Juneja on the Armed Cell Therapeutics acquisition and CAR-T therapy entry. The Economic Times provides the deepest breakdown, including brand-wise growth, prescription share, and consumer healthcare segment weakness.
Coverage: 4 sources, 4 neutral
Sources (4): cnbctv18.com (neutral report), economictimes.indiatimes.com (neutral report), thehansindia.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Methodology and corrections.
